Turalio First FDA-Approved Systemic Therapy for Tenosynovial Giant-Cell Tumor

Web Exclusives - FDA Updates

On August 2, 2019, the FDA approved pexidartinib (Turalio; Daiichi Sankyo) capsules, a kinase inhibitor, for adults with symptomatic tenosynovial giant-cell tumor (TGCT), which is associated with severe morbidity or functional limitations, who are not candidates for surgery. Pexidartinib is the first systemic therapy approved for patients with TGCT. The FDA granted pexidartinib a priority review and breakthrough therapy and orphan drug designations.

The FDA approval was based on the international, multicenter, randomized (1:1), double-blind, placebo-controlled clinical trial of 120 patients with TGCT that could not be removed by surgery. The primary end point was durable overall response rate (ORR), as determined by an independent review committee at week 25.

Patients were randomized in a 1:1 ratio to pexidartinib or to placebo. After 25 weeks, the ORR was 38% (95% confidence interval, 27-50), including 15% complete responses and 23% partial responses, with pexidartinib versus no responses with placebo (P <.0001). Overall, 22 patients who responded to pexidartinib therapy maintained the response for ≥6 months. In addition, 13 patients maintained the response for ≥12 months.

Patients with enough data had significant improvement in the range of motion of the affected joint at week 25 with pexidartinib versus placebo.

The most common side effects with pexidartinib were increased lactate dehydrogenase, increased aspartate aminotransferase, hair color changes, increased alanine aminotransferase, and increased cholesterol. Pexidartinib was approved with a boxed warning about the risk for fatal liver injury; the drug is only available through a Risk Evaluation and Mitigation Strategy program.

Related Items
FDA News
TOP - May 2020, Vol 13, No 3 published on May 21, 2020 in FDA Updates
Opdivo-Yervoy First Immunotherapy Combo Approved for First-Line Therapy of Patients with Metastatic NSCLC
Web Exclusives published on May 18, 2020 in FDA Updates, Lung Cancer
Tabrecta First FDA-Approved Targeted Therapy for Metastatic NSCLC and MET Exon 14 Skipping
Web Exclusives published on May 11, 2020 in FDA Updates
Retevmo First Therapy Approved for 3 Types of Cancers with RET Mutations
Web Exclusives published on May 11, 2020 in FDA Updates
FDA Approves Darzalex Faspro as Subcutaneous Formulation for All Patients with Multiple Myeloma
Web Exclusives published on May 5, 2020 in FDA Updates
Zejula First PARP Inhibitor Approved as First-Line Maintenance Treatment for All Patients with Ovarian Cancer
Web Exclusives published on May 4, 2020 in FDA Updates
FDA Approves New 400 mg Every-6-Weeks Dosing Regimen of Keytruda for All Indications
Web Exclusives published on April 30, 2020 in FDA Updates
Jelmyto First FDA-Approved Therapy for Low-Grade Upper-Tract Urothelial Cancer
Web Exclusives published on April 21, 2020 in FDA Updates, Urothelial Cancer
FDA Grants Priority Review to New Drug Application for the RET Kinase Inhibitor Selpercatinib
Web Exclusives published on February 4, 2020 in FDA Updates, In the News, Lung Cancer, Thyroid Cancer
Tazverik Receives FDA Approval as First Treatment Specifically for Metastatic or Locally Advanced Epithelioid Sarcoma
Web Exclusives published on January 28, 2020 in FDA Updates, In the News, Sarcoma
Last modified: April 27, 2020